Please assess the completion status of the following clinical trial:

Trial Title: Effects of Donepezil on Regional Cerebral Blood Flow Following Aneurysmal Subarachnoid Haemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 - 85 years~* Fisher score 2-4~* recruitment within 12 - 72 hours of hemorrhage~Exclusion Criteria:~* pregnancy~* breast feeding~* allergy to donepezil or other piperidine derivatives~* participants unwilling to use appropriate birth control up to 6 weeks after enrolment~* known dementia~* severe liver failure (Child-Pugh C)~* sick sinus syndrome or other supraventricular cardiac conduction abnormalities~* inspired oxygen requirement greater than 60%~* history of brittle asthma or obstructive airway disease~* aneurysm unsuitable for endovascular coiling~* concomitant use of cholinesterase inhibitor (e.g. rivastigmine, galantamine, etc)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Donepezil (Type: ACTIVE_COMPARATOR): Participants in the donepezil arm will receive the drug for 21 days as specified in the protocol in addition to current best medical treatment for aSAH patients.
- Control (Type: NO_INTERVENTION): Control group participants will not receive a placebo drug but will undergo cerebral blood flow imaging in the same manner as the donepezil patients. All other aspects of treatment will be identical to that of aSAH patients not involved in the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).